Product Description
Thiotepa is used in high-dose chemotherapy (HDT) before autologous hematopoietic stem cell transplantation (HSCT) to treat solid tumors and hematological malignancies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31428821/)
Mechanisms of Action: CYP2B6 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | United States | Uruguay
Approved Indications: Breast Diseases | beta-Thalassemia | Thalassemia | Adenocarcinoma | Bladder Cancer | Breast Cancer | Papillary Adenocarcinoma | Papillary Carcinoma | Oncology Unspecified | Urinary Bladder Diseases
Known Adverse Events: Mucositis | Anemia | Neutropenia | Hematuria | Diarrhea
Company: NKI-AVL
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Primary Central Nervous System Lymphoma
Phase 2: Neuroblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VERITAS | P2 |
Active, not recruiting |
Neuroblastoma |
2025-02-07 |
|
| MATRix / IELSG43 | P3 |
Completed |
Primary Central Nervous System Lymphoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma |
2022-02-25 |